Informations générales (source: ClinicalTrials.gov)
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart (FACS)
Interventional
N/A
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
mars 2010
octobre 2017
29 juin 2024
The purpose of this study is to analyze the association of atrial fibrillation onset in
normal heart and:
- Genetic determinants (genes of receptors, enzymes involved in synthesis and
degradation, genes of bioavailability of coenzymes and nutritional precursors)
- Metabolic determinants of adenosine and methionine cycles
- Nutritional determinants.
Secondary purposes are:
- Analysis of physiopathologic mechanisms of AF in normal hearts and adenosine
metabolisms and its interaction with methionine metabolism, according to identified
genetic determinants
- Analysis of blood markers of adenosine and methionine metabolites as phenotypic
markers of detected polymorphisms
- Evaluate the role of adenosine receptors in AF onset
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Département de Cardiologie, CHU Nancy, Hôpitaux de Brabois - Vandoeuvre Les Nancy - France | Etienne ALIOT, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Informed consent
- Affiliation to French social security plan
AF in normal heart:
- Atrial fibrillation in normal heart
Control:
- Junctional supraventricular tachycardia in normal heart
Normal heart: absence of macroscopic cardiomyopathy (echocardiography and normal ejection
fraction)
- Informed consent
- Affiliation to French social security plan
AF in normal heart:
- Atrial fibrillation in normal heart
Control:
- Junctional supraventricular tachycardia in normal heart
Normal heart: absence of macroscopic cardiomyopathy (echocardiography and normal ejection
fraction)
- Considerable consumption of coffee (> 50 mg/day, 15 cups/day)
- Actual administration of drugs interfering with adenosine metabolism: dipyridamole
and methotrexate
- Actual administration interfering with methionine metabolism: folates, methotrexate
and anticonvulsants
- Known renal insufficiency
- Known hypo- or hyperthyroidism
- Refusal or impossibility of informed consent
- Pregnant or breastfeeding women
- Person deprived of liberty
- Person under legal protection or not able to consent
- Person in emergency situation